To summarize and critically discuss current evidence on comorbidities, treatment challenges, unmet needs, and future directions in pediatric psoriasis.
Approach:
Literature Review: A comprehensive search was performed in PubMed/MEDLINE, Google Scholar, and ClinicalTrials.gov from January 1, 2000, to December 1, 2025, using specific search terms related to pediatric psoriasis.
Key Findings:
Pediatric psoriasis is associated with multiple comorbidities, including obesity, cardiometabolic risk factors, psychological disorders, and inflammatory conditions such as psoriatic arthritis.
Therapeutic options have expanded with pediatric-specific biologic therapies; however, management remains challenging due to access barriers, age restrictions, off-label use, and limited long-term safety data.
Major unmet needs include delayed drug development, limited evidence beyond plaque psoriasis, insufficient evaluation of extracutaneous outcomes, and the lack of updated therapeutic algorithms for pediatric patients.
Interpretation:
Limitations:
Lack of updated international guidelines for treatment strategies and comorbidity screening in pediatric patients.
Clinical decision-making often relies on extrapolation from adult data and consensus-based recommendations.
Conclusion:
Future advances will require pediatric-focused research, improved understanding of the disease biology, and integrated multidisciplinary strategies to optimize long-term outcomes.
Federal prosecutors allege that a Florida physician and research staff fabricated clinical trial records that were submitted into database systems used to evaluate investigational drugs.
